Genomic Vision strengthens team

Appoints chief finance officer and vice president of research and development

Genomic Vision, a biotechnology company dedicated to DNA analysis with an innovative molecular combing nanotechnology, has appointed Erwan Martin as chief financial officer and Emmanuel Conseiller as vice president of research and development.

Prior to joining Genomic Vision, Martin was cfo at Cytomics Pharmaceuticals (2003–2008), a biopharmaceutical company he co-founded with Dominique Thomas (Research Director at the CNRS Centre for Molecular Genetics, Gif-sur-Yvette) and for which he led the first rounds of financing. Prior to this he worked for 10 years as a consultant for Syndex, an auditing firm.

Conseiller joined Genomic Vision in 2009 after working for more than 17 years as a senior manager at sanofi-aventis (primarily within the oncology division). He is a pioneer in the application of functional genomics to drug discovery (from drug target screening to clinical trials) and has designed and led several projects for drug screening (small molecules and gene therapy) in the fields of tumour suppression, DNA replication and tumour metabolism. He holds a PhD from Pierre and Marie Curie University, Paris. In 1997, he won the Rhone-Poulenc Rorer Research Prize for his work on the development of chimeric tumour suppressors for gene therapy of cancer.

You may also like

Research & Development

Quotient Sciences extends partnership for ultra-rare disease treatment

This collaboration reinforces Quotient Sciences’ commitment to supporting the manufacture of niche and smaller volume commercial products often overlooked by larger CDMOs
Research & Development

OSE Immunotherapeutics receives positive IDMC review for Phase III ARTEMIA trial

OSE Immunotherapeutics SA has received a second positive recommendation from the Independent Data Monitoring Committee to continue its Phase III ARTEMIA trial of Tedopi in advanced non-small cell lung cancer
Research & Development

Vilnius University scientists reveal new role for CRISPR-Cas9 in bacterial immunity

The researchers report in Molecular Cell that the CRISPR-Cas9 protein plays a previously unknown role in selecting and integrating viral DNA fragments during bacterial immune memory formation
Research & Development

Lilly’s Orforglipron beats oral semaglutide in Phase III ACHIEVE-3 trial with superior weight loss

Head-to-head data published in The Lancet show Eli Lilly's oral GLP-1 candidate orforglipron delivered significantly greater HbA1c reductions and weight loss than oral semaglutide in adults with type 2 diabetes, supporting global regulatory submissions
Regulatory

Johnson & Johnson files FDA application for IMAAVY in wAIHA

Johnson & Johnson has submitted an sBLA to the US Food and Drug Administration seeking approval of IMAAVY as the first-ever treatment for warm autoimmune haemolytic anaemia, supported by Phase II/III ENERGY trial data showing rapid and durable haemoglobin response
Research & Development

Almirall advances etherna’s mRNA/LNP therapy LAD116 into IND-enabling studies

Almirall has selected LAD116, developed using etherna's intratumoral mRNA/LNP platform, for IND-enabling studies in non-melanoma skin cancer, marking a key milestone toward GMP manufacturing and Phase I clinical trials
Research & Development

SPARK THE MIDLANDS backs Aston University anti-cancer bone paste collaboration

A collaboration between Aston University and Royal Orthopaedic Hospital NHS Foundation Trust has secured support from SPARK THE MIDLANDS to advance a minimally invasive gallium-doped injectable paste for treating primary and metastatic bone cancer
Subscribe now